Mesoblast is a world leader in developing innovative cellular medicines.

The Company has established what it believes is the industry’s most clinically advanced and diverse portfolio of cell-based product candidates with three programs in Phase 3 clinical studies. Consistent and durable clinical outcomes have been demonstrated across multiple difficult-to-treat diseases

Our lead product candidates under investigation are:

  • remestemcel-L for acute graft versus host disease
  • Revascor for advanced heart failure
  • MPC-06-ID for chronic low back pain due to disc degeneration
  • MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy

Mesoblast also has a strong emerging pipeline of products for follow-on indications.

The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates.

Its allogeneic, ‘off-the-shelf’ cell product candidates are being evaluated in a range of advanced-stage diseases with high, unmet medical needs, including cardiovascular diseases, musculoskeletal disorders, immune-mediated and inflammatory conditions and oncologic and hematologic diseases.

It is Mesoblast’s goal to have the first industrially manufactured allogeneic mesenchymal lineage cell-based product approved in the United States with its product candidate for the treatment in children of acute graft versus host disease, a life-threatening complication of a bone marrow transplant. Mesoblast’s licensee in Japan, JCR Pharmaceuticals Co. Ltd., is marketing its mesenchymal stem cell-based product for the treatment of this disease in children and adults. TEMCELL® HS Inj. was the first allogeneic cellular medicine to receive full approval in Japan.

Prioritized Portfolio of Clinically Distinct and Advanced Product Candidates

Each of Mesoblast’s product candidates has its own distinct technical characteristics, target indications, individual reimbursement strategy, separate commercialization potential, and unique partnering opportunities.

The majority of time and resources are focused on developing Tier 1 product candidates. Tier 2 programs are also in development and may advance to Tier 1 depending on the merit of newly generated data, market opportunity or partnering options.

Lead Product Candidates under Clinical Investigation

remestemcel-L is a Phase 3 intravenously-delivered product candidate that is being developed for the treatment of acute graft versus host disease following allogeneic bone marrow transplantation. An open label trial using remestemcel-L in children with steroid-refractory acute Graft Versus Host Disease is being conducted to support filing of a biologic license application to the United States Food and Drug Administration (FDA) for regulatory approval. This Phase 3 trial has successfully met the primary endpoint of Day 28 overall response.  There are no products currently approved in the United States for treatment of steroid-refractory aGVHD in children under 12. Given the serious nature of this condition, in 2017 the FDA granted Fast Track designation for the use of remestemcel-L to achieve improved overall response rate in children with aGVHD. Mesoblast believes that successful results from the completed Phase 3 trial through Day 100, together with Day 180 safety and quality of life parameters in these patients, may provide sufficient clinical evidence for filing for remestemcel-L in the United States under an accelerated approval pathway.  Mesoblast plans to evaluate the use of remestemcel-L in adult patients with high-risk steroid-refractory acute graft versus host disease.

Revascor is a late-stage cardiovascular product candidate for patients with advanced and end-stage heart failure. The mechanism of action by which Revascor is thought to exert its effects in these patient populations is through secretion of potent biomolecules which reduce damaging inflammation and strengthen the native heart by induction of a mature blood vessel network.

Approximately half of people who develop heart failure die within five years of diagnosis. Patients with advanced chronic heart failure (defined as New York Heart Association Class III or Class IV) have the highest burden of disease, recurrent hospitalizations and mortality. A Phase 3 trial is enrolling patients with chronic heart failure across North America. The trial’s primary efficacy endpoint is a comparison of recurrent non-fatal heart failure-related major adverse cardiac events between either patients treated with Revascor or sham-treated controls. In April 2017, this trial achieved a successful pre-specified interim futility analysis of the efficacy endpoint in the first 270 patients of the 600-patient trial. Based on this outcome, an independent data monitoring committee formally recommended the continuation of the trial. 

Enrollment has been completed in a Phase 2b trial sponsored by the United States National Institutes of Health and the Canadian Institute of Health Research   evaluating Revascor in 159 patients with end-stage heart failure requiring a left ventricular assist device (LVAD). In this patient population, despite optimal medical therapy, one-year mortality is around 30%. 

The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for Mesoblast’s mesenchymal precursor cell therapy in the treatment of heart failure patients with left ventricular systolic dysfunction and LVADs. The RMAT designation under the United States 21st Century Cures Act aims to expedite the development of regenerative medicine therapies intended for the treatment of serious diseases and life-threatening conditions. 

The basis of this RMAT designation grant came from the completed study data set of a 30-patient randomized, blinded, placebo-controlled pilot trial of Mesoblast’s MPCs at a dose of 25 million cells in heart failure patients with LVADs, and related analyses. These preliminary clinical data suggest that Mesoblast’s MPC product   improved native heart function, prolonged the time post LVAD implantation of a first hospitalization for a non-surgical major gastrointestinal bleeding event, and improved early survival rates in these LVAD recipients.

MPC-06-ID is a non-opioid alternative for the treatment of chronic low back pain due to disc degeneration. When disc degeneration has progressed to a point that pain and loss of function can no longer be managed by conservative means such as   medication and physiotherapy, major invasive surgery such as spinal fusion is the only remaining option. Existing therapies treat the symptoms of the disease, but are not disease-modifying and thus do not address the underlying disease cause. As a result, the Company believes the most significant unmet need is a therapy that can not only improve the patient’s pain and function, but has the ability to reverse, halt or slow disease progression. 

Phase 2 results demonstrated that a single injection of MPC-06-ID resulted in meaningful improvements in both pain and function that were durable for at least 36 months. By treating the cause of chronic blow back pain, MPC-06-ID could fill an unmet treatment gap for a large population of patients. A Phase 3 trial of 360 patients is actively enrolling patients in the United States and Australia.

MPC-300-IV is an intravenously-delivered immunomodulatory product candidate for the treatment of chronic inflammatory conditions, including biologic-refractory rheumatoid arthritis, a chronic autoimmune disease of unknown etiology that affects approximately one percent of the population. The disease is attributed to chronic inflammation affecting the synovial membrane of multiple joints, which eventually leads to cartilage and bone destruction. The health-related quality of life in patients with rheumatoid arthritis is significantly impaired by pain, fatigue, and decline in musculoskeletal function. It is also associated with an increased risk of cardiovascular disease and mortality. 

The rheumatoid arthritis population resistant to anti-tumor necrosis factor agents constitutes about one-third of patients treated with these agents. The goal of therapy in these patients is to achieve early and sustained low disease activity which correlates with prevention of structural joint damage in rheumatoid arthritis. 

In a 48-patient randomized, placebo-controlled Phase 2 trial in biologic refractory rheumatoid arthritis a single intravenous infusion of MPC-300-IV was well tolerated, without serious adverse events, and demonstrated a dose-related improvement in clinical symptoms, physical function, and disease activity relative to placebo through the 12-week primary endpoint and durability through the 39-week follow-up period of this 52-week study. 

MLC Technology Platform

Mesoblast’s proprietary mesenchymal lineage cells are central to blood vessel maintenance, repair and regeneration, largely via the secretion of growth factors that act on neighbouring endothelial cells to promote blood vessel regeneration and function. These rare cells (approximately 1:100,000) are found around blood vessels and respond to signals associated with tissue damage, secreting mediators that promote tissue repair and modulate immune responses.

The Company’s 'off-the-shelf' product candidates are allogeneic and immune-privileged, meaning cells from one donor may be used in many different recipients without the need for tissue matching

Mesoblast’s proprietary cells have two distinct technical properties:

Expansion – proprietary methods have been developed that enable the large-scale expansion of mesenchymal lineage cells while maintaining their ability to produce key biomolecules associated with tissue health and repair. This allows production of a cellular product with consistent, well-defined therapeutic properties, batch release criteria and established potency assays, with accompanying manufacturing economies of scale.

Immune Privilege – mesenchymal lineage cells are immune privileged, meaning they do not initiate and facilitate an immune response when administered to unrelated patients. Based on extensive preclinical studies, the mechanisms that contribute to the lack of immune response appear to be multi-factorial and involve lack of immune stimulatory molecule expression, as well as release of various biomolecules involved in the inhibition of immune responses.

Mesenchymal lineage cells can be taken from healthy young adult donors from various tissue sources, including bone marrow, fat tissue and dental pulp. Mesoblast isolates these cells from bone marrow and expands these to create master cell banks, which are then further amplified to generate thousands of therapeutic doses without the need for tissue matching. Each allogeneic product candidate is packaged into vials, frozen, and then transported to medical facilities for use in clinical trials worldwide.

Robust Intellectual Property Position

Mesoblast’s intellectual property portfolio encompasses approximately 800 patents or patent applications across 69 patent families, which the Company believes will provide substantial competitive advantages for the commercial development of its cell-based therapies in major markets including the United States, Europe, Japan and China. These cover compositions of matter and uses for mesenchymal lineage-based technologies and other proprietary regenerative medicine product candidates and technologies, as well as for elements of proprietary manufacturing processes.

World Class Stem Cell Science and Translational Medicine

Mesoblast's approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent criteria set by international regulatory agencies.

Strategic Alliances

Mesoblast has established strategic relationships with several industry leaders to support clinical development, manufacturing and commercial capabilities.

JCR Pharmaceuticals Co. Ltd has been granted an exclusive right in Japan to Mesoblast's mesenchymal stem cell technology for use in conjunction with the treatment of hematologic malignancies using hematopoietic stem cell transplants derived from peripheral blood, cord blood or bone marrow.

An alliance with the Lonza Group was established to ensure long-term commercial manufacturing requirements of our products. The Company believes this alliance provides Mesoblast with significant commercial advantages, including capacity to meet long-term global supply of its proprietary product candidates, dedicated access to Lonza's cell therapy facilities in Singapore, and the potential for a purpose-built manufacturing facility to be built by Lonza to meet Mesoblast's long-term commercial objectives.

Experienced Management Team

Led by Chief Executive Dr Silviu Itescu, a pioneer of cellular medicines, Mesoblast employs approximately 80 employees in the United States, Australia and Singapore.


Mesoblast was publically listed on the Australian Securities Exchange (ASX:MSB) in December 2004. The Company has a Level 3 American Depositary Receipt program facility and listed on the Nasdaq (Nasdaq: MESO) in the United States in November 2015